drugset / Trial / NCT06946927
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Timeline
- Start
- 2025-06-06
- Primary completion
- 2026-02
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Ifebemtinib | Small molecule | — | Oral |
| Subject | JMKX001899 | Unknown | — | Oral |
| Subject | Pemetrexed | Small molecule | — | Intravenous |